The DOI matches its Crossref record; 89 of the 95 references it cites were found in a registry or an index; 36 of the 76 sources its claims cite were checked for support.
Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis
Open accessAbstract
Context: Polycystic ovary syndrome (PCOS) affects more than 1 in 10 women. Objective: As part of the 2023 International PCOS Guidelines update, comparisons between combined oral contraceptive pills (COCP), metformin, and combination treatment were evaluated. Data Sources: Ovid Medline, Embase, PsycINFO, All EBM, and CINAHL were searched. Study Selection: Women with PCOS included in randomized controlled trials (RCTs). Data Extraction: We calculated mean differences and 95% CIs regarding anthropometrics, metabolic, and hyperandrogenic outcomes. Meta-analyses and quality assessment using GRADE were performed. Data Synthesis: The search identified 1660 publications; 36 RCTs were included. For hirsutism, no differences were seen when comparing metformin vs COCP, nor when comparing COCP vs combination treatment with metformin and COCP. Metformin was inferior on free androgen index (FAI) (7.08; 95% CI 4.81, 9.36), sex hormone binding globulin (SHBG) (−118.61 nmol/L; 95% CI −174.46, −62.75) and testosterone (0.48 nmol/L; 95% CI 0.32, 0.64) compared with COCP. COCP was inferior for FAI (0.58; 95% CI 0.36, 0.80) and SHBG (−16.61 nmol/L; 95% CI −28.51, −4.71) compared with combination treatment, whereas testosterone did not differ. Metformin lowered insulin (−27.12 pmol/L; 95% CI −40.65, −13.59) and triglycerides (−0.15 mmol/L; 95% CI −0.29, −0.01) compared with COCP. COCP was inferior for insulin (17.03 pmol/L; 95% CI 7.79, 26.26) and insulin resistance (0.44; 95% CI 0.17, 0.70) compared with combination treatment. Conclusions: The choice of metformin or COCP treatment should be based on symptoms, noting some biochemical benefits from combination treatment targeting both major endocrine disturbances seen in PCOS (hyperinsulinemia and hyperandrogenism).
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis of 36 RCTs compared metformin, combined oral contraceptive pills (COCP), and combination treatment in women with PCOS. COCP was superior for cycle regularity and some androgen outcomes, metformin was superior for metabolic outcomes, and combination treatment improved biochemical hyperandrogenism and insulin measures over COCP alone.
Key findings
- Among 36 RCTs, metformin was inferior to COCP for free androgen index (MD 7.08; 95% CI 4.81–9.36), SHBG (MD −118.61 nmol/L; 95% CI −174.46 to −62.75), and total testosterone (MD 0.48 nmol/L; 95% CI 0.32–0.64), with no overall hirsutism difference; metformin was superior for fasting insulin (MD −27.12 pmol/L; 95% CI −40.65 to −13.59), triglycerides (MD −0.15 mmol/L; 95% CI −0.29 to −0.01), total cholesterol (MD −0.40 mmol/L; 95% CI −0.66 to −0.14), and CRP (MD −11.31 nmol/L; 95% CI −19.78 to −2.85).
- Metformin was inferior to COCP for restoring regular menses (OR 0.17; 95% CI 0.05–0.57).
- COCP alone was inferior to COCP plus metformin for FAI (MD 0.58; 95% CI 0.36–0.80), SHBG (MD −16.61 nmol/L; 95% CI −28.51 to −4.71), DHEAS (MD 0.93 μmol/L; 95% CI 0.54–1.31), androstenedione (MD 1.37 nmol/L; 95% CI 0.14–2.60), fasting insulin (MD 17.03 pmol/L; 95% CI 7.79–26.26), HOMA-IR (MD 0.44; 95% CI 0.17–0.70), and CRP (MD 1.94 nmol/L; 95% CI 0.05–3.84), with no difference in hirsutism or total/free testosterone.
- Metformin alone was inferior to combination treatment for DHEAS (MD 82.38 μmol/L; 95% CI 15.43–149.36) and total testosterone (MD 0.64 nmol/L; 95% CI 0.26–1.02), but had marginally lower fasting glucose (MD −0.33 mmol/L; 95% CI −0.64 to −0.01) and CRP (MD −4.08 nmol/L; 95% CI −6.01 to −2.16).
Methods
- Systematic review and meta-analysis conducted for the 2023 International PCOS Guidelines update, following PRISMA and registered in PROSPERO (CRD42022345640). Searches of Ovid Medline, Embase, PsycINFO, All EBM, and CINAHL covered 2017 to July 7, 2022, plus re-evaluation of the previous 1946–2017 search; 1660 publications were identified, 450 full texts reviewed, plus 176 from the previous search, yielding 36 RCTs in 46 publications.
- Included RCTs of women with PCOS (Rotterdam, NIH, or AES criteria) comparing metformin, COCP, or COCP plus metformin; outcomes included anthropometric, metabolic, androgenicity, psychological, and adverse-event measures.
- Random-effects meta-analyses used Review Manager 5.4.1, calculating mean differences and 95% CIs for continuous outcomes and odds ratios and 95% CIs for dichotomous outcomes; risk of bias was assessed with RoB2 and certainty with GRADE, with subgroup analyses by BMI, age, and COCP type.
Limitations
- Paper-stated limitations: many included studies had high risk of bias (20 high, 14 some concerns, 2 low), often due to poorly described randomization or lack of blinding; certainty of evidence was affected by inconsistency of effect sizes and small sample sizes; several studies did not provide BMI data; adverse effects could not be meta-analyzed due to lack of systematic reporting; health-related quality of life could not be meta-analyzed; research gaps include lack of larger studies in adolescents and of metformin versus combination treatment.
- Evident from the text: most GRADE certainty ratings were low or very low, and several comparisons relied on few studies or participants, limiting precision and generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Included studies are shown in the PRISMA flowchart. The search was performed for 3 medical treatments (combined oral contraceptive pills [COCP], metformin, and anti-androgens) as part of the update of the PCOS guidelines. Results comparing COCP, metformin, and combined COCP and metformin were included in this systematic review.](https://figures.cochat.ai/paper-figures/f16a047520ca4fdab3992ca8422ca06c/metformin-and-combined-oral-contraceptive-pills-in-the-management-of-polycystic-figure-1.jpg)

Verification
Claims the paper makes
24 Valid · 4 Not valid · 29 Not checked · 105 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Two systematic reviews found that adding metformin to COCP and anti-androgens improved BMI and glucose tolerance (11, 88).”
§ Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis > Discussion > Interpretation
What the sources say
- Disputedcites [11] Luque-Ramírez, 2018, Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis, Hum Reprod Update sourceExperimental — accuracy not yet measured
In “Meta-analyses of primary outcomes” (page not provided), the paper says adding metformin to antiandrogenic therapy yielded no advantage in glucose measured after an oral glucose tolerance test. It reports a reduction in fasting glucose with combined therapy, but that is a different outcome from the claimed improvement in glucose tolerance. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [88] Wu, 2023, Oral contraceptives (OCs) in combination with metformin versus OCs alone on metabolism in nonobese polycystic ovary syndrome: a meta-analysis and systematic review of randomized controlled trials, Clin Endocrinol sourceExperimental — accuracy not yet measured
The Overall results (§3.5.1) report lower fasting glucose with metformin plus oral contraceptives than with oral contraceptives alone in nonobese women with PCOS. The review does not report a glucose-tolerance outcome or evaluate adding metformin to a separate anti-androgen treatment, so those parts of the attributed claim are not established. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“COCP does not have any major effects on carbohydrate metabolism in healthy women, whereas the effect on lipid metabolism depends on the level of estrogen and type of progestin, with potential negative effects (78, 79, 80, 81).”
§ Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis > Discussion > Interpretation
What the sources say
- Not checked — no full text of the sourcecites [78] Korytkowski, 1995, Metabolic effects of oral contraceptives in women with polycystic ovary syndrome, J Clin Endocrinol Metab source
- Disputedcites [79] Piltonen, 2012, Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sesitivity in young healthy normal-weight women: a randomized study, Hum Reprod sourceExperimental — accuracy not yet measured
The Discussion (page not supplied) reports that insulin sensitivity decreased in the oral contraceptive group, with increased insulin levels and worsened measures of glucose tolerance. Although fasting glucose remained unchanged, the paper concludes that the contraceptives studied had unfavourable effects on glucose metabolism—contrary to the attributed claim. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
- Supportedcites [80] Lopez, 2019, Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus, Cochrane Database Syst Rev source
The Discussion (Summary of main results) states that combined hormonal contraceptives do not cause clinically important changes in carbohydrate metabolism in women without diabetes. This supports the claim about COCPs and carbohydrate metabolism; the review notes that no trial was placebo-controlled. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several studies have shown that metformin may improve biochemical hyperandrogenism and anovulation (9, 10).”
§ Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis > Abstract > Conclusions
What the sources say
- Supportedcites [9] Naderpoor, 2015, Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis, Hum Reprod Update source
The metformin-alone results (p. 10) report lower total testosterone than lifestyle treatment, supporting a possible improvement in biochemical hyperandrogenism. The Discussion (p. 13) reports improved menstrual cyclicity with metformin added to lifestyle treatment and cites evidence of improved ovulation in women with PCOS. It also notes that adding metformin did not improve biochemical hyperandrogenism relative to lifestyle plus placebo, so the effects depend on the comparison. (LLM, conf=0.88)
- Not matchedcites [10] RCOG, 2017, Metformin therapy for the management of infertility in women with polycystic ovary syndrome: scientific impact paper No. 13, BJOG
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Generally combined oral contraceptive pills (COCP) are regarded as more effective than metformin for the management of hyperandrogenism and menstrual regulation in PCOS (11, 12).”
§ Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis > Abstract > Conclusions
What the sources say
- Supportedcites [11] Luque-Ramírez, 2018, Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis, Hum Reprod Update source
The Principal findings section says COC and antiandrogen therapy was superior to insulin sensitizers for low-to-moderate hyperandrogenic symptoms in women with PCOS not pursuing pregnancy. The Meta-analyses of primary outcomes section reports that regular menses favoured COC over metformin. Page numbers are unavailable in our copy. (LLM, conf=0.91)
- Partly supportedcites [12] Teede, 2019, Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: a systematic review with meta-analyses, Clin Endocrinol (Oxf) sourceExperimental — accuracy not yet measured
The COCP-versus-metformin results for adults (section 3.6, p. 6) favor COCP for androgen measures and irregular cycles. In adolescents (section 3.5, p. 6), COCP improved menstrual regulation more, but the review found no significant difference in the reported androgen measures. The claim is therefore supported for adults, but its broad hyperandrogenism comparison across PCOS is not fully supported. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“COCPs containing cyproterone acetate (CPA) might be more effective in reducing hirsutism compared to conventional COCPs (14, 15);”
§ Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis > Abstract > Conclusions
What the sources say
- Partly supportedcites [14] De Leo, 2016, Hormonal contraceptives: pharmacology tailored to women's health, Hum Reprod Update sourceExperimental — accuracy not yet measured
The PCOS section reports that CPA improved hirsutism compared with placebo. The Acne and hirsutism section describes CPA as an anti-androgen that can be used in a contraceptive pill when COCs alone do not work. Neither passage establishes that CPA-containing COCs reduce hirsutism more effectively than conventional COCs; page numbers are unavailable in our copy. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [15] Amiri, 2018, Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis, Eur J Contracept Reprod Health Care source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
111 more claims · 8 with their cited sources checked
Create a free account to see all 162 claims and every source verdict.
- Probably not a substantial claim. 37
- It may state two separate claims as one. 13
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“adolescents (MD −30.03 pmol/L; 95% CI, −78.63 to −18.56)”
§ Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis > Results > Metabolic Outcomes
Reported -30.03 · recomputed -48.595
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis > Results > Anthropometric Outcomes
“Metformin was superior in lowering WHR (MD −0.03; 95% CI, −0.06 to −0.01) compared with metformin, with no difference in BMI (Table 5).”
§ Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis > Results > Meta-analyses
“Table: Table 5. Grade assessments and evidence profile of outcomes in PCOS comparing metformin with metformin and combined oral contraceptive pills”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis > Results > Study Selection
“all studies used 30 to 35 µg ethinylestradiol (EE)”
§ Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis > Results > Study Selection
“C2: 20μg EE + 100μg LVG + 50 mg SPL (low dose)***”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis > Discussion > Interpretation
“In our meta-analysis, there were no differences in weight, WHR, and BMI”
§ Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis > Results > Meta-analyses
“| Overall | 2 | Seriousa | No serious | No serious | Very seriouse | 18 | 16 | −0.03 (−0.06 to −0.01) | Metformin | ⨁◯◯◯VERY LOW |”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Self-citationBozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E., & Yildiz, B. O. (2016) · Human Reproduction · doi:10.1093/humrep/dew218 · Cited by 1,526
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., Andersen, M., Azziz, R., et al. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.004 · Cited by 1,325
Self-citationJoham, A. E., Norman, R. J., Stener-Victorin, E., Legro, R. S., Franks, S., Moran, L. J., Boyle, J., & Teede, H. J. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00163-2 · Cited by 838
Self-citation
Research works printed but not linked: 2
- Schünemann, GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations
- Aghamohammadzadeh, 2010, Comparison of metformin and cyproterone-estrodiol compound effect on HS C-reactive protein and serum androgen levels in patients with polycystic ovary syndrome, Pak J Med Sci, 2, 347
Cited by
Stener-Victorin, E., Teede, H., Norman, R. J., Legro, R., Goodarzi, M. O., Dokras, A., Laven, J., Hoeger, K., & Piltonen, T. T. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00511-3 · Cited by 495
“…a meta-analysis showed that COCP treatment results in lower free androgen index, total and free testosterone, androstenedione, and dehydroepiandrosterone sulfate levels along with higher SHBG levels than metformin treatment; however, hirsutism did not differ between the treatments 251 .”
Self-citationInternational evidence-based recommendations for polycystic ovary syndrome in adolescents
Peña, A. S., Witchel, S. F., Boivin, J., Burgert, T. S., Ee, C., Hoeger, K. M., Lujan, M. E., Mousa, A., Oberfield, S. E., Tay, C. T., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-03901-w · Cited by 123
“Metformin could be used over COCP for metabolic features and COCP could be used over metformin for hirsutism and/or menstrual irregularities based on four studies (142 adolescents) [1, 43].”
Self-citationFroldi, G. (2024) · Pharmaceuticals · doi:10.3390/ph17040478 · Cited by 82
“…of 46 RCTs has been performed as a 2023 update of the “International Evidence-based Guidelines for the Assessment and Management of PCOS”, highlighting that metformin is superior to hormonal treatment in controlling the blood sugar, overweight, and lipid profile of PCSO subjects [207,208].”
MethodPrevalence, Phenotypes, and Comorbidities of Polycystic Ovary Syndrome Among Indian Women
Ganie, M. A., Chowdhury, S., Malhotra, N., Sahay, R. K., Bhattacharya, P. K., Agrawal, S., Jabbar, P. K., Suri, V., Rozati, R., Sreenivas, V., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.40583 · Cited by 104
Saadati, S., Mason, T., Godini, R., Vanky, E., Teede, H. J., & Mousa, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16422 · Cited by 117
“141 Earlier meta-analyses – one in non-obese women (14 RCTs) 142 and another in the broader PCOS population (33 RCTs) 143 – found that adding metformin to COCPs or anti-androgens improved BMI and glucose tolerance compared with hormonal therapy alone.”
Self-citation
Metadata
- Authors
- Melin, J., Forslund, M., Alesi, S., Piltonen, T., Romualdi, D., Spritzer, P. M., Tay, C. T., Pena, A., Witchel, S. F., Mousa, A., & Teede, H.
- Affiliations
- University of Helsinki (FI)
- Monash University (AU)
- Oulu University Hospital (FI)
- Agostino Gemelli University Polyclinic (IT)
- Universidade Federal do Rio Grande do Sul (BR)
- Discipline of Paediatrics, The University of Adelaide and Robinson Research Institute , Adelaide, South Australia 5005 , Australia
- Children's Hospital of Pittsburgh (US)
- Monash Medical Centre (AU)
- Corresponding author
- Melin, Johanna
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2023-08-09
- Volume
- 109
- Issue
- 2
- Pages
- e817-e836
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC10795934
- OpenAlex
- W4385679942
- Cited by
- 78
- References
- 95
- Citations by year
- 2026: 29 · 2025: 31 · 2024: 17 · 2023: 1
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc-nd)
- Työväentutkimus Vuosikirja (submittedVersion)
- Funders
- The Medical Society of Finland
- Orion Research foundation
- Iris foundation
- Hjalmar Svensson Foundation
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, metformin, combined oral contraceptives, combination therapy, hirsutism, free androgen index, sex hormone-binding globulin, testosterone, insulin, insulin resistance, triglycerides, hyperandrogenism, ovulation induction, pregnancy outcomes, cardiovascular risk, quality of life
- MeSH terms
- Contraceptives, Oral, Combined, Female, Humans, Hypoglycemic Agents, Metformin, Polycystic Ovary Syndrome, Testosterone, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1210/clinem/dgad465
- The paper
- Melin, J., Forslund, M., Alesi, S., Piltonen, T., Romualdi, D., Spritzer, P. M., Tay, C. T., Pena, A., Witchel, S. F., Mousa, A., & Teede, H. (2024). Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad465
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.